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ABSTRACT
Background and aims: Obese and diabetic mice display
enhanced intestinal permeability and metabolic endotox-
aemia that participate in the occurrence of metabolic
disorders. Our recent data support the idea that a
selective increase of Bifidobacterium spp. reduces the
impact of high-fat diet-induced metabolic endotoxaemia
and inflammatory disorders. Here, we hypothesised that
prebiotic modulation of gut microbiota lowers intestinal
permeability, by a mechanism involving glucagon-like
peptide-2 (GLP-2) thereby improving inflammation and
metabolic disorders during obesity and diabetes.
Methods: Study 1: ob/ob mice (Ob-CT) were treated with
either prebiotic (Ob-Pre) or non-prebiotic carbohydrates as
control (Ob-Cell). Study 2: Ob-CT and Ob-Pre mice were
treated with GLP-2 antagonist or saline. Study 3: Ob-CT
mice were treated with a GLP-2 agonist or saline. We
assessed changes in the gut microbiota, intestinal
permeability, gut peptides, intestinal epithelial tight-junction
proteins ZO-1 and occludin (qPCR and immunohistochem-
istry), hepatic and systemic inflammation.
Results: Prebiotic-treated mice exhibited a lower plasma
lipopolysaccharide (LPS) and cytokines, and a decreased
hepatic expression of inflammatory and oxidative stress
markers. This decreased inflammatory tone was asso-
ciated with a lower intestinal permeability and improved
tight-junction integrity compared to controls. Prebiotic
increased the endogenous intestinotrophic proglucagon-
derived peptide (GLP-2) production whereas the GLP-2
antagonist abolished most of the prebiotic effects. Finally,
pharmacological GLP-2 treatment decreased gut perme-
ability, systemic and hepatic inflammatory phenotype
associated with obesity to a similar extent as that
observed following prebiotic-induced changes in gut
microbiota.
Conclusion: We found that a selective gut microbiota
change controls and increases endogenous GLP-2
production, and consequently improves gut barrier
functions by a GLP-2-dependent mechanism, contributing
to the improvement of gut barrier functions during obesity
and diabetes.
Obesity is typically associated with a cluster of
several metabolic disorders, characterised by a low-
grade inflammation.1 2 Evidence that the gut
microbiota composition can be different between
healthy and obese and/or type 2 diabetic patients
has led to the investigation of this environmental
element as a key factor in the pathophysiology of
metabolic diseases.3–5
We previously reported that the gut microbiota
is involved in high-fat diet-induced metabolic
endotoxaemia, adipose tissue inflammation and
metabolic disorders.6–9 The link between high-fat
diet-induced inflammation, oxidative stress, meta-
bolic disorders, and gut microbiota, could be
lipopolysaccharide (LPS)-dependent.7 10–14 Several
pieces of clinical and experimental data have
confirmed that LPS significantly contributes to
the development of obesity-related inflammatory
liver diseases such as non-alcoholic fatty liver
disease and non-alcoholic steatohepatitis.15–17 High
plasma LPS levels could result from an increased
production of endotoxin upon changes in the gut
microbiota.7 8 Normally, the intestinal epithelium
acts as a continuous barrier to avoid LPS transloca-
tion; yet some endogenous or exogenous events
may alter this protective function. Among the
elements promoting a leaky gut, and thus an
increased plasmatic LPS level, are alcohol consump-
tion,15 18–22 immobilisation stress,23 24 and radiation25
have been proposed. In addition, we have recently
shown that the modulation of gut bacteria
following a high-fat diet strongly increases intest-
inal permeability, by reducing the expression of
genes coding for two tight junction proteins ZO-1
and occludin.6 We previously reported that gut
bacteria are clearly involved in these events since
obese and high-fat fed-diabetic mice treated with
an antibiotic recovered normal intestinal epithelial
integrity.6 Also, recent data have shown that obese
and diabetic mice display enhanced intestinal
permeability, and are characterised by a metabolic
endotoxaemia and a low-grade inflammation.6 7 26
Furthermore, high-fat feeding changes gut micro-
biota6–8 27 towards a decreased number of bifido-
bacteria,6–8 a group of bacteria which has been
shown to reduce intestinal LPS levels in mice and
to improve the mucosal barrier function.28–32
Besides, we have shown that feeding mice with
prebiotics increased the number of intestinal
bifidobacteria and reduced the impact of high-fat
diet-induced metabolic endotoxaemia and inflam-
matory disorders.8 33
Importantly, however, the mechanisms linking
prebiotic-induced changes in gut microbiota, meta-
bolic endotoxaemia and the improvement of
obesity-related hepatic and metabolic disorders
are still unknown.
By using these experiments, we have tested the
hypothesis that the control of gut permeability
through the selective modulation of gut microbiota
by prebiotics participates in the improvement of
metabolic diseases in ob/ob mice. Novel mechan-
isms involving the influence of gut fermentation
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on specific proglucagon-derived peptides – namely, glucagon-
like peptide-2 (GLP-2) – are proposed.
MATERIALS AND METHODS
Animals
Experiment 1
Six-week-old ob/ob (n = 10/group) mice (C57BL/6 background;
Jackson Laboratory, Bar Harbor, Maine, USA) were housed in a
controlled environment (12 h daylight cycle, lights off at 18.00
hours) in groups of 2 mice/cage, and kept with free access to
food and water. The mice were fed a control diet (Ob-CT) (A04,
Villemoisson sur Orge, France), or a control diet containing a
mix of a fermentable dietary fibre (oligofructose) (Ob-Pre)
(Orafti, Tienen, Belgium),33 or a diet containing a mix a non-
fermentable dietary fibre (microcrystalline cellulose) (Ob-Cell)
(Vivapur Microcrystalline cellulose; J. Retten Maier 38 So¨hne,
Weissenborn, Germany). Dietary fibres were added in a
proportion of 9:1 (weight of control diet:weight of fibres).
Experiment 2
Six-week-old ob/ob (n = 8/group) mice (C57BL/6 background;
Jackson Laboratory) were housed in a controlled environment
(12 h daylight cycle, lights off at 18.00 hours) in groups of
2 mice/cage, and kept with free access to food and water. To
study the significance of GLP-2 in this model, mice were injected
subcutaneously twice daily for 4 weeks with 2.5 mg/kg of GLP-2
receptor antagonist GLP-2 (3–33) (Eurogentec, Verviers,
Belgium) as described34–36 or saline. The mice were fed a control
diet and injected with saline or GLP-2 antagonist (Ob-CT and
Ob-Ant, respectively), or fed the prebiotic diet and injected with
saline or GLP-2 antagonist (Ob-Pre and Ob-Pre-Ant, respec-
tively).
Experiment 3
Six-week-old ob/ob (n = 6/group) mice (C57BL/6 background;
Jackson Laboratory) were housed in a controlled environment
(12 h daylight cycle, lights off at 1800 hours) in groups of
2 mice/cage, and kept with free access to food and water. The
mice were fed the same control diet as described in experiment
1. The mice were separated into two groups and injected
subcutaneously twice daily for 12 days with 25 mg GLP-2 (1–33)
(Bachem, Bubendorf, Switzerland) (Ob-GLP-2), or saline (Ob-
CT). GLP-2 doses were based on previous studies describing the
physiological effects (ie, the intestinotrophic properties) of the
peptides.35 37–39
Tissue sampling
Mice were anaesthetised (ketamine/xylazine, intraperineally,
100 and 10 mg/kg, respectively) after a 5 h period of fasting, and
blood samples and tissues were harvested for further analysis.
Mice were killed by cervical dislocation. Liver, caecum (full and
empty), muscles (vastus lateralis), and adipose tissues (epididy-
mal, subcutaneous and visceral) were precisely dissected and
weighed. The intestinal segments (jejunum, colon) were
immersed in liquid nitrogen, and stored at 280uC, for further
analysis.
Microbial analysis of the caecal content of selected mice
Metagenomic DNA was extracted from the caecal content of
randomly selected mice (5/group), using the QIAamp DNA stool
mini kit (Qiagen, Venlo, Netherlands) according to the manu-
facturer’s instructions. Denaturing gradient gel electrophoresis
(DGGE) on total bacteria, bifidobacteria and lactobacilli were
performed to study the qualitative effect of the treatment on the
structure and composition of the intestinal microbial commu-
nity.40 DGGE with a 45–60% denaturant gradient were used to
separate the polymerase chain reaction (PCR) products obtained
with a nested approach for the 16S rRNA genes of bifidobacteria
(primers BIF164f-BIF662r) and lactobacilli (SGLAB0158f-
SGLAB0667). The first PCR round was followed by a second
amplification with primers 338F-GC and 518R. The latter primers
were also used to amplify the 16S rDNA of all bacteria on total
extracted DNA. The DGGE patterns obtained were subsequently
analysed using the Bionumerics software version 2.0 (Applied
Maths, Sint-Martens-Latem, Belgium).41 In brief, the calculation
of the similarities was based on the Pearson (product–moment)
correlation coefficient. Clustering analysis was performed using
the unweighted pair group method with arithmetic mean
clustering algorithm (UPGMA) to calculate the dendrograms of
each DGGE gel and a combination of all gels. The latter was
performed on a created composite dataset. Multidimensional
scaling (MDS) analysis was used to reduce the different data of
the complex DGGE patterns of one sample to one point in a three-
dimensional space. MDS was based on the combined information
from the distance matrices of each DGGE, obtained using
similarity coefficients (Pearson correlation).
Quantitative PCR (qPCR) for total bacteria (using primers
PRBA338f and P518r) and specific for bifidobacteria, lactobacilli
or the Eubacterium rectale/Clostridium coccoides grp. was per-
formed to study the quantitative effect of the treatment on the
composition of the intestinal microbial community as reported
by Possemiers et al.42
Real-time qPCR
Total RNA from tissues was prepared using the TriPure reagent
(Roche, Basel, Switzerland) as described.33 cDNA was synthe-
sised using a reverse transcription kit (Promega, Madison,
Wisconsin, USA) from 1 mg of total RNA. qPCR was performed
with a STEP one PLUS instrument and software (Applied
Biosystems, Foster City, California, USA), as described.6 Primer
sequences for the targeted mouse genes are presented in
supplemental table 1.
Immunofluorescence analysis of occludin and ZO-1
Jejunum segments were immediately removed, washed with
PBS, mounted in embedding medium (Tissue-Tek, Sakura,
Netherlands), and stored at 280uC until use. Cryosections
(5 mm) were fixed in acetone at 220uC for 5 min for occludin
and fixed in ethanol for 30 min at room temperature and in
acetone at 220uC for 5 min for ZO-1. Non-specific background
was blocked by incubation with 10% bovine serum albumin
(BSA) in Tris-buffered saline (TBS) and 0.3% Triton X-100
(30 min at room temperature). Sections were incubated with
rabbit anti-occludin or rabbit anti-ZO-1 (1:400 for ZO-1 and
1:100 for occludin staining; Zymed Laboratories, San Francisco,
California, USA) for 2 h. Sections were washed three times for
10 min in TBS and probed with goat anti-rabbit fluorescein
isothiocyante (FITC)-conjugated antibodies (1:50, Zymax;
Zymed Laboratories). Slides were washed three times for
10 min in TBS and mounted in mounting medium
(Vectashield; Vector Laboratories, Burlingame, California,
USA). Sections were visualised on a fluorescence microscope
using a 640 objective, and images were stored digitally with
Leica software. As a control, slides were incubated with serial
dilutions of the primary antibody to signal extinction. Two
negative controls were used: slides incubated with irrelevant
Inflammatory bowel disease
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antibody or without primary antibody. All the stainings were
performed in duplicate in non-serial distant sections, and analysed
in a double-blind manner by two different investigators.
Intestinal permeability in vivo
This measure is based on the intestinal permeability towards
4000 Da fluorescent dextran–FITC (DX-4000–FITC) (FD4000;
Sigma-Aldrich, St. Louis, Missouri, USA) as described.6 43 Briefly,
mice that had fasted for 6 h were given DX-4000–FITC by
gavage (500 mg/kg body weight, 125 mg/ml). After 1 h and 4 h,
120 ml of blood was collected from the tip of the tail vein. The
blood was centrifuged at 4uC, 12 000 g for 3 min. Plasma was
diluted in an equal volume of PBS (pH 7.4) and analysed for DX-
4000–FITC concentration with a fluorescence spectrophot-
ometer (HTS-7000 Plus-plate-reader; Perkin Elmer, Wellesley,
Massachusetts, USA) at an excitation wavelength of 485 nm
and emission wavelength of 535 nm. Standard curves were
obtained by diluting FITC–dextran in non-treated plasma
diluted with PBS (1:3 v/v).
Biochemical analyses
Plasma LPS concentration was determined by using a kit based
upon a Limulus amoebocyte extract (LAL kit endpoint-
QCL1000; Cambrex BioScience, Walkersville, Maryland, USA),
samples were diluted 1/40 to 1/100 and heated for 20 cycles of
10 min at 68uC and 10 min at 4uC. An internal control for LPS
recovery was included in the calculation. Plasma cytokines
(interleukin (IL) 1a, IL1b, tumour necrosis factor (TNF) a, IL6,
monocyte chemoattractant protein (MCP)-1, macrophage
inflammatory protein (MIP)-1a, IL10, interferon (INF) c, IL15,
IL18) and gut hormones (GLP-1 (active), GIP (total), amylin
(active), pancreatic polypeptide) were respectively determined
in duplicate by using a Bio-Plex Multiplex kit (Bio-Rad,
Nazareth, Belgium), or a mouse gut hormones panel
(LincoPlex; Millipore, Brussels, Belgium), and measured by
using Luminex technology (Bio-Rad Bioplex; Bio-Rad) following
the manufacturer’s instructions, an EIA kit (GLP-2 EIA kit)
(Yanaihara Institute, Shizuoka, Japan) was used to quantify
GLP-2.
Statistical analysis
Results are presented as mean with the SEM. The statistical
significance of differences was analysed by one-way ANOVA
followed by post hoc Bonferroni’s multiple comparison test or
Kruskal–Wallis for non-parametric data followed by Dunn’s
multiple comparison test. Data with different superscript letters
are significantly different p,0.05, according to the post hoc
ANOVA statistical analysis. Comparisons between GLP-2-
treated mice and control mice were performed using the
two-tailed Student t test. Multiple correlation analyses were
assessed by the Pearson’s test using GraphPad Prism version 5.00
for windows. Results were considered statistically significant
when p,0.05.
RESULTS
Prebiotic treatment induces changes in the gut microbiota of ob/
ob mice
Feeding ob/ob mice with the prebiotic carbohydrates (Ob-Pre)
induced significant changes in the gut microbiota of the caecum,
with a higher total bacteria count, Lactobacillus spp.,
Bifidobacterium spp., and the C coccoides–E rectale cluster
(table 1), as compared to the control mice (Ob-CT and Ob-Cell).
Changes in the microbial community composition were also
observed upon DGGE analysis of the caecal content of the
different treatment groups (fig 1A–C). Clustering of the DGGE
fingerprints for total bacteria and for the specific groups of
bifidobacteria and lactobacilli, indicated, for all fingerprints, a
separate cluster of the Ob-Pre mice. Secondary clustering was
observed between the Ob-CT and Ob-Cell mice. Finally, multi-
dimensional scaling (MDS) analysis, performed on the composite
data set derived from the combination of all the DGGE analyses of
this study (total bacteria, lactobacilli and bifidobacteria), also
indicated a specific clustering pattern, depending on the treatment
of the ob/ob mice. (fig 1D). As the distance between 2 data points
in the three-dimensional MDS plot is a visual representation of
the difference in the microbial community composition of the
caecum of the different mice, MDS analysis provides the final
confirmation that the prebiotic treatment induced important
changes in the gut microbiota of the Ob-Pre mice compared to the
control groups.
Changes in the gut microbiota upon prebiotic administration
reduce intestinal permeability
Ob-Pre fed mice exhibited a 3-fold lower plasma DX-4000–FITC
area under the curve (fig 2A) as compared to Ob-CT and Ob-
Cell mice. In accordance with the in vivo assessment of
intestinal permeability, LPS levels were significantly lower in
Ob-Pre mice plasma samples, as compared to the other groups
(fig 2B). Moreover, plasma DX-4000–FITC and portal plasma
LPS levels were positively and significantly correlated (fig 2B,
inset), further confirming the relation between intestinal
permeability and the development of metabolic endotoxaemia.
Gut permeability is controlled by several specific tight-junction
proteins. Among these, ZO-1 and occludin have been proposed
as key markers of tight-junction integrity.26 The prebiotic
treatment increased ZO-1 and occludin mRNA in the jejunum
segment (fig 2C,F). As previously suggested, a representative
immunofluorescence assay performed on intestinal sections of
wild-type C57BL/6J mice demonstrated an intact network of
ZO-1 and occludin proteins which were predominantly localised
along the apical cellular border.26 In strong contrast, ZO-1 and
occludin staining appears to be decreased and discontinuous in
Ob-CT tissues (fig 3A,B). Furthermore, immunohistochemical
Table 1 Prebiotic-associated changes in gut microbiota
Bacterial content Ob-CT Ob-Cell Ob-Pre
Total bacteria 5.74a (2.05) 4.30b (0.38) 8.07c (1.05)
Bifidobacterium spp 4.65a (1.58) 3.38b (0.37) 6.35c (1.10)
Lactobacillus spp 4.93a (1.76) 3.79a (0.38) 7.16b (1.40)
Clostridium coccoides–Eubacterium rectale cluster 3.65a (1.37) 2.72a (0.20) 6.41b (1.27)
Results are given as the log DNA copies/caecal content (SD).
Data are mean with the SD.
Data with different superscript letters are significantly different p,0.05, according to the post hoc ANOVA statistical analysis.
CT, Cell and Pre, respectively, refer to the selected ob/ob mice fed a normal-diet, non-prebiotic control diet or prebiotic diet.
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score analysis confirmed the strong alteration of ZO-1 and
occludin distribution and expression as compared to wild-type
mice (fig 2E,H). In accordance with the mRNA analysis,
prebiotic feeding improved the tight junctions, since the
immunohistochemical staining of both proteins localised along
the apical cellular border was higher in Ob-Pre as compared to
Ob-CT and Ob-Cell mice (fig 3A,B).
To identify whether the changes in the gut microbiota and
tight-junction protein expression are associated with in vivo gut
permeability, multiple correlation analysis between these
parameters was performed. Indeed, a negative correlation
between tight-junction proteins mRNA and plasma DX-4000–
FITC was found in the jejunum segment (fig 2D,G), and in the
colon (supplementary data 1). In addition, the caecal content of
Bifidobacterium spp. and portal plasma levels of LPS showed a
negative correlation (supplemental data 1), suggesting that the
specific increase of bifidobacteria positively impacted the
development of metabolic endotoxaemia.
Changes in the gut microbiota upon prebiotic administration are
associated with improved systemic and hepatic inflammation
To study the effects of changes in the gut microbiota and
improved barrier function on the one hand, and metabolic
disorders on the other hand, we first assessed systemic
inflammation. All plasma cytokine and chemokine concentra-
tions were decreased in Ob-Pre mice when compared to Ob-CT
and Ob-Cell mice (fig 4). Metabolic endotoxaemia is frequently
associated with hepatic inflammation, and with increased
oxidative stress driving metabolic disorders. Here we found that
changing the gut microbiota significantly reduced plasminogen
activator inhibitor 1 (PAI-1), CD68, NADPH oxidase (NADPHox)
and inducible nitric oxide synthase (iNOS) mRNA concentrations
(fig 5A,B,E,F), and tended to decrease toll-like receptor 4 (TLR4)
and TNFa mRNA concentrations (fig 5I,J). The oxidative stress
marker NADPHox positively correlated with macrophage infiltra-
tion markers (CD68, TLR4) (fig 5 C,D). Moreover, both
macrophage infiltration markers were correlated (fig 5G).
Plasma chemokine MCP-1 positively correlated with tissue
macrophages infiltration and oxidative stress markers (fig 5
H,K,L). Accordingly, plasma LPS levels were positively correlated
with NADPHox and macrophage infiltration markers (liver CD68
mRNA and plasma MCP-1 levels) (supplemental data 1).
Furthermore, we found that these markers were negatively
correlated with the content of Bifidobacterium spp. (supplemental
data 1). The lower inflammatory and oxidative stress was
associated with a lower total hepatic lipid content (Ob-CT: 839a
(SEM 111); Ob-Cell: 781a (SEM 42); Ob-Pre: 531b (SEM 58) mg of
lipids/liver, Ob-Pre p,0.05 vs Ob-CT and Ob-Cell) and confirmed
by histological analysis (not shown). (Different superscript letters
denote a statistical difference between the groups.) Altogether,
these multiple correlations support a strong relationship between
gut microbiota, gut permeability, systemic and hepatic inflamma-
tion, oxidative stress and macrophage infiltration in ob/ob mice.
Prebiotic feeding modulates plasma gut peptides and adiposity
Prebiotic administration decreased food intake (Ob-CT: 24.9a
(SEM 0.7); Ob-Cell: 20.0b (SEM 0.5); Ob-Pre: 16.3c (SEM
1.1) kcal/day.mouse; p,0.05). We have previously demon-
strated that prebiotic-induced changes in the gut microbiota
modulate gastrointestinal peptides (GLP-1, peptide YY (PYY),
Figure 1 Prebiotic-associated changes
in the gut microbiota. DGGE fingerprint
patterns of the caecal microbial
community of selected ob/ob mice fed a
normal-diet (Ob-CT, white symbols), non-
prebiotic control diet (Ob-Cell, grey
symbols) or prebiotic diet (Ob-Pre, black
symbols) for 5 weeks. The DGGE profiles
were constructed using primers for
(A) Total bacteria (B) Bifidobacterium spp
(C) Lactobacillus spp. Cluster analysis is
based on the Pearson product–moment
correlation coefficient and UPGMA
linkage. (D) Three-dimensional
multidimensional scaling analysis
conducted on the DGGE fingerprinting
composite data set (total bacteria,
Bifidobacterium spp. and Lactobacillus
spp). CT, Cell and Pre respectively refer to
the selected ob/ob mice fed a normal-diet,
non-prebiotic control diet or prebiotic diet
for 5 weeks. DGGE, denaturing gradient
gel electrophoresis;
UPGMA, unweighted pair group method
with arithmetic mean clustering
algorithm.
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ghrelin) involved in glucose homeostasis, appetite and/or body
weight regulation.8 33 44–48 Here, we found that the prebiotic
treatment also modulated portal plasma gut peptides in ob/ob
mice, leading to a significant increase in GLP-1 (table 2). In
addition, the glucose-dependent insulinotropic polypeptides
(GIPs), another peptide associated with the development of
obesity, diabetes and adiposity, was significantly decreased
(table 2).49–51 In accordance with this, Ob-Pre mice had lower
visceral, epididymal and subcutaneous adipose depots and a
higher muscle mass as compared to the other groups (supple-
mental data 2).
This study is the first in which it is shown that, besides an effect
on gut peptides, feeding prebiotics also modulated two pancreatic
peptides, since it significantly increased amylin (table 2) and
decreased pancreatic polypeptide (PP) as compared to Ob-CT and
Ob-Cell mice (table 2). The link between the above-mentioned
peptides modulated by prebiotics and gut permeability has not
been described so far. Moreover, the decrease in food intake and/or
a decrease in adiposity are not involved in changes in gut
permeability. Thus, we have hypothesised that GLP-2, a peptide
clearly related to GLP-1 production, could link changes in gut
microbiota and intestinal barrier function.
Prebiotic administration increases intestinal proglucagon mRNA
and portal plasma proglucagon-derived peptide GLP-2
We and other have previously shown that changing gut
microbiota by using fermentable non-digestible carbohydrate
significantly increases gut weight and promotes proliferation of
epithelial cells.52–54 We have also shown – and confirmed in the
present study (table 2) – that feeding mice with prebiotic doubled
GPL-1 portal plasma levels.8 33 44 45 47 48 55 56 In previous studies, the
increase in GLP-1 plasma level was associated with a higher GPL-1
peptide and proglucagon mRNA expression in the (proximal)
colon tissue. Interestingly, our study is the first to show that a
Figure 2 Prebiotic treatment reduces intestinal permeability. (A) Intestinal permeability assay: Plasma DX-4000–FITC (mg/ml) oral challenge
measured in ob/ob mice fed a normal diet (Ob-CT), non-prebiotic control diet (Ob-Cell), prebiotic diet (Ob-Pre) for 5 weeks. The inset corresponds to the
area under curve (AUC) in the same groups. (B) Plasma endotoxin (LPS) concentrations (EU/ml); the inset corresponds to correlation between plasma
LPS levels and plasma DX-4000–FITC (Pearson’s r correlation and corresponding p value). (C,F) Jejunum epithelial tight-junction protein markers (ZO-1
and occludin mRNA concentrations) relative expression to Ob-CT. Data are mean with the SEM. Data with different superscript letters are significantly
different (p,0.05), according to the post hoc ANOVA statistical analysis. (D,G) Correlations between intestinal permeability markers: plasma
DX-4000–FITC and ZO-1 and occludin mRNA concentrations (p,0.05); the inset corresponds to Pearson’s r correlation and corresponding p value.
(E,H) Immunohistochemistry score of the jejunum epithelial tight-junction proteins (ZO-1 and occludin) in wild-type (CT), Ob-CT, Ob-Cell or Ob-Pre mice.
DX-4000, dextran of molecular weight 4000 Da; EU, endotoxin unit; FITC, fluroescein isothiocyanate; LPS, lipopolysaccharide.
Inflammatory bowel disease
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higher proglucagon mRNA content occurs in the proximal colon –
as expected – and also in the jejunum (fig 6A,B). Among the
proglucagon-derived peptides, GLP-2 is co-secreted with GLP-1
and exerts an intestinotrophic effect.39 57 58 GLP-2 enhances in-
testinal epithelial proliferation and reduces gut permeability,59–62
hence, we found that Ob-Pre fed mice exhibited a significant
increase of plasma GLP-2 levels (table 2). Importantly, portal
plasma GLP-2 and both plasma markers of gut permeability (DX-
4000–FITC and LPS) were negatively correlated (fig 6C,D). Along
the same line, intestinal proglucagon and tight-junction mRNA
(ZO-1, occludin) were positively correlated (fig 6E,F). Altogether,
these data suggest that the prebiotic-induced intestinal progluca-
gon mRNA enhanced expression and the consequent GLP-2
production indicate that this peptide may positively impacts on
gut barrier integrity.
Chronic GLP-2 antagonist treatment blunts prebiotic-induced
reduction in endotoxaemia and hepatic inflammatory tone
To causally link changes in endogenous GLP-2 production upon
prebiotic treatment with the improvement of metabolic endotox-
aemia, and inflammatory markers, we chronically blocked GLP-2
receptor in prebiotic fed ob/ob mice by using GLP-2 antagonist.
In this second set of experiments, we confirm the data
observed in the first study showing that prebiotic-induced
changes in gut microbiota are linked to a significant decrease in
plasma LPS levels, hepatic inflammation and oxidative stress
markers such as PAI-1, CD68, NADPHox and TLR4 mRNA
concentrations (fig 7B–D,F), and to a tendency to decrease for
iNOS and TNFa mRNA concentrations (fig 7E,G). In addition,
we also confirm that the prebiotic treatment increases ZO-1 and
Figure 3 Prebiotic treatment changes tight-junction proteins
distribution. Representative immunofluorescence staining for (A) ZO-1
and (B) occludin in ob/ob mice fed a normal diet (Ob-CT), non-prebiotic
control diet (Ob-Cell), prebiotic diet (Ob-Pre) for 5 weeks. WT, wild-type.
Figure 4 Prebiotic treatment reduces the occurrence of systemic
inflammation. (A) IL1a, (B) IL1b, (C) TNFa, (D) MCP-1, (E) MIP-1a,
(F) INFc, (G) IL6, (H) IL10, (I) IL18 and (J) IL15 plasma levels (pg/ml) in
ob/ob mice fed a normal diet (Ob-CT), non-prebiotic control diet (Ob-Cell)
or prebiotic diet (Ob-Pre) for 5 weeks. Data are mean with the SEM. Data
with different superscript letters are significantly different (p,0.05),
according to the post hoc ANOVA statistical analysis. IFN, interferon;
IL, interleukin; MCP-1, monocyte chemoattratant protein-1;
MIP-1a, macrophage inflammatory protein-1a; TNF, tumour necrosis factor.
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occludin mRNA (fig 7H) and the GLP-2 precursor transcript
(proglucagon mRNA) content in the jejunum (fig 7I).
Importantly, the GLP-2 antagonist completely blunts the
prebiotic-induced reduction endotoxaemia (fig 7A). Hence, most
of the prebiotic-induced changes of hepatic inflammation and
oxidative stress markers are also controlled by a GLP-2-dependent
mechanism. We observed that mice treated concomitantly with
the prebiotic and the GLP-2 antagonist or GLP-2 antagonist alone
exhibit CD68, NADPHox and TLR4 mRNA levels (fig 7B–D)
similar to the control mice, except for the PAI-1 mRNA levels
(fig 7F) which remains equivalent to the prebiotic treated mice
with or without GLP-2 antagonist treatment. Moreover, GLP-2
antagonist treatment completely blocked the enhanced progluca-
gon, ZO1 and occludin mRNA levels found in prebiotic fed mice
that reach values similar to the control (fig 7H,I).
Chronic GLP-2 pharmacological treatment lowers endotoxaemia,
improves gut permeability markers, and reduces systemic and
hepatic inflammation, oxidative stress and macrophage
infiltration markers
To study the impact of a pharmacological GLP-2 treatment,
without modulation of the gut microbiota, we treated ob/ob
mice with GLP-2 for 12 days. Body weight, food intake,
adiposity, liver weight were equivalent between Ob-CT mice
and Ob-GLP-2 mice (supplemental data 3).
Importantly, we demonstrated that GLP-2 administration to
ob/ob mice dramatically decreased plasma LPS by about 50%
(fig 8A). This was accompanied by a lower plasma inflammatory
tone (IL1a, MIP-1a, MCP-1, IL10) (fig 8B–E)). Furthermore, as
reported in both prebiotics-fed mice studies, mRNA concentra-
tions of macrophage infiltration (TLR4, CD68) (fig 8G,I),
inflammation (TNFa, PAI-1) (fig 8F,J) and oxidative stress
(iNOS, NADPHox) markers (fig 8H,K) were decreased in Ob-
GLP-2 mice as compared to Ob-CT mice. Finally, ZO-1 and
occludin staining immunohistochemical score analysis confirmed
the strong impact of GLP-2 on the tight-junctions proteins (fig 8L).
In accordance with the prebiotic effect, the immunohistochemical
staining of both proteins localised along the apical cellular border
was higher in Ob-GLP-2 as compared to Ob-CT (fig 8M).
Therefore, the gut peptide GLP-2 appears as a credible link
between gut microbiota, gut permeability, and inflammatory tone.
DISCUSSION
Several reports have demonstrated that the gut microbiota
participates in the development of obesity by several mechan-
isms, ie, by harvesting energy from the diet, by modulating the
Figure 5 Changes in the gut microbiota control hepatic inflammation, oxidative stress and macrophage infiltration markers. (A,I) Inflammation: PAI-1,
TNFa mRNA concentrations; (B,J) Macrophage infiltration markers: CD68, TLR4 mRNA concentrations; (E,F) Oxidative stress markers: NADPHox, iNOS
mRNA concentrations in ob/ob mice fed a normal diet (Ob-CT), non-prebiotic control diet (Ob-Cell) or prebiotic diet (Ob-Pre) for 5 weeks. Data are mean
with the SEM. Data with different superscript letters are significantly different (p,0.05), according to the post hoc ANOVA statistical analysis.
Correlations between liver NADPHox mRNA and (C) liver CD68 mRNA, (D) TLR4 mRNA or (K) plasma MCP-1 levels. Correlations between plasma MCP-
1 and (H) liver CD68 mRNA or (L) TLR4 mRNA. (G) Correlation between liver CD68 mRNA and TLR4 mRNA concentrations (p,0.05) the inset
corresponds to Pearson’s r correlation and corresponding p value. iNOS, inducible nitric oxide synthase; MCP-1, monocyte chemoattractant protein-1;
NADPHox, NADPH oxidase; PAI-1, plasminogen activator inhibitor; TLR, toll-like receptor; TNF, tumour necrosis factor.
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synthesis of gut peptides involved in energy homeostasis, and/or
by regulating fat storage.63 We have recently demonstrated that
mice fed a high-fat diet were characterised by an increase in gut
permeability and metabolic endotoxaemia. The inflammatory
phenotype of ob/ob mice originates from the gut microbiota,
since changing the gut microbiota using antibiotics lowers
endotoxaemia-induced inflammation and metabolic disor-
ders.6 64 65 Recently, it has been proposed that this higher
endotoxaemia in ob/ob mice and db/db mice was dependent on
a disruption of the key tight-junction proteins, ZO-1 and
occludin.26 Here we confirm that obese mice exhibit an altered
gut barrier, characterised by a disruption of tight-junction
proteins. Among the mechanisms involved in this phenomenon,
excessive TNFa production was proposed to help propagate the
extension of a local or systemic inflammation and this
inflammatory process per se would trigger the alteration of
both junctional proteins.24 Our data show that prebiotic-fed
mice have a lower level of several plasma cytokines well-known
to promote tight-junction disruption such as TNFa, IL1b, IL1a,
IL6, INFc.66–69 In addition, we also found a significant decrease of
the chemokines MCP-1 and MIP-1a.
In the present study, we demonstrated, in two separate set of
experiments, that changing gut microbiota of ob/ob mice in
favour of the Bifidobacterium spp. is associated with a significant
improvement of gut permeability measured in vivo; this
phenomenon was linked to an increase in tight-junction
mRNA expression and proteins distribution. The improved
gut barrier observed in prebiotic-fed mice was correlated to the
lower portal plasma LPS levels and inflammatory tone (ie,
decrease in circulating cytokines). The leakage of gut micro-
biota-derived LPS into the portal blood is a well-established
mechanism of metabolic endotoxaemia that triggers liver
inflammation and oxidative stress.26 70 In the present studies,
we found that lowering systemic inflammation by prebiotics is
significantly correlated with a strong decrease in markers of
oxidative and inflammatory stress in the liver tissue. Altogether,
Table 2 Changes in the gut microbiota upon administration of prebiotics impacts on portal plasma gut
peptides
Gut peptide Ob-CT Ob-Cell Ob-Pre
GLP-1 (active) (pmol/l) 7.65a (1.52) 7.71a (1.62) 21.15b (6.71)
GIP (total) (pg/ml) 207.91a (37.76) 180.71a (27.53) 114.02b (16.92)
Pancreatic polypeptide (pg/ml) 68.07a (8.45) 75.94a (6.56) 50.05b (2.67)
Amylin (active) (pg/ml) 358.87a (36.12) 364.99a (45.07) 504.90b (58.34)
GLP-2 (ng/ml) 0.56a (0.06) 0.62a (0.04) 0.75b (0.05)
Data are mean (SEM).
Data with different superscript letters are significantly different at p,0.05, according to the post hoc ANOVA statistical analysis.
CT, Cell and Pre, respectively, refer to the selected ob/ob mice, fed a normal diet, non-prebiotic control diet or prebiotic diet.
GIP, glucose-dependent insulinotropic polypeptide; GLP, glucogon-like peptide.
Figure 6 Prebiotic administration increases intestinal proglucagon mRNA and correlates with intestinal permeability markers. (A) Jejunum
proglucagon mRNA concentrations; (B) proximal colon proglucagon mRNA concentrations in ob/ob mice fed a normal diet (Ob-CT), non-prebiotic
control diet (Ob-Cell), prebiotic diet (Ob-Pre) for 5 weeks. Data are mean with the SEM. Data with different superscript letters are significantly different
(p,0.05), according to the post hoc ANOVA statistical analysis. Correlations between plasma GLP-2 levels and (C) plasma LPS plasma; or (D) DX-
4000–FITC plasma levels. Correlations between proglucagon mRNA and (E) jejunum ZO-1 or (F) occludin mRNA concentrations; the inset corresponds
to Pearson’s r correlation and corresponding p value. DX 4000, dextran of molecular weight 4000 Da; FITC, fluorescein isothiocyanate;
GLP-2, glucogon-like protein-2; LPS, lipopolysaccharide.
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these data strongly suggest that the modulation of the gut
microbiota using prebiotics in obese mice, could act favourably
on the intestinal barrier, thereby reducing endotoxaemia,
systemic and liver inflammation, with beneficial consequences
on associated metabolic disorders.
However, the mechanisms by which prebiotics improve gut
permeability – in the particular context of obesity – are not fully
understood. One potential explanation could arise from the
putative role of the Bifidobacterium spp in maintaining the gut
barrier. Interestingly, Bifidobacterium spp do not degrade
intestinal mucus glycoproteins like other pathogenic bacteria
do, and Bifidobacterium spp promote a healthier microvillus
environment by preventing permeability and bacterial translo-
cation.71 72 Among the putative mechanisms, it has been
demonstrated that the prebiotic modulation of the gut
microbiota increases villus height and crypt depth, and leads
to a thicker mucosal layer in the jejunum and in the colon.73
These effects are related to the bacterial fermentation of the
prebiotics. The resulting products of fermentation are mainly
short-chain fatty acids (SCFAs), with butyrate acting as an
energetic substrate for the colonocytes and having a trophic
effect on mucosa.74 75 In epithelial monolayers model, it has been
shown that other probiotics strains such as Lactobacillus
rhamnosus GG and Lactobacillus casei DN-114-001 protect
epithelial barrier function against Escherichia coli-induced redis-
tribution of the tight-junction proteins.76 77 Besides the putative
role of the SCFAs and specific bacterial strains, the exact
mechanism underlying the relation between prebiotic-induced
changes in gut microbiota and improved gut barrier function
has not been described so far.
Here we found that changes in the gut microbiota of ob/ob
mice exert a trophic effect on the intestine of Ob-Pre mice, a
phenomenon associated with a higher proglucagon mRNA
expression in both the jejunum and colon. We have previously
demonstrated that prebiotic-induced changes in the gut micro-
biota promote GLP-1 synthesis (proglucagon mRNA and GLP-1
Figure 7 Chronic GLP-2 antagonist treatment blunts prebiotic-induced reduction in endotoxaemia and hepatic inflammatory tone. (A) Plasma LPS
concentrations (EU/ml); (B,D) Macrophage infiltration markers: TLR4, CD68mRNA concentrations; (C,E) oxidative stress markers: NADPHox, iNOS
mRNA concentrations; (F,G) hepatic inflammation: PAI-1, TNFa mRNA concentrations; (H) jejunum epithelial tight-junction protein markers (ZO-1 and
occludin mRNA) concentrations; (I) jejunum proglucagon mRNA concentrations in ob/ob mice fed a normal diet and injected twice daily with a saline
(Ob-CT), prebiotic diet and injected twice daily with a saline (Ob-Pre), prebiotic diet and injected twice daily with GLP-2 antagonist (ObPre-Ant), normal
diet and injected twice daily with GLP-2 antagonist (Ob-Ant) for 4 weeks. Data are mean with the SEM. *Significantly different (p,0.05) from Ob-CT
and Ob-Pre-Ant according to the Kruskal–Wallis test analysis. Data with different superscript letters are significantly different (p,0.05), according to
the post hoc ANOVA statistical analysis. EU, endotoxin unit; GLP-2, glucagon-like protein-2; iNOS, inducible nitric oxide synthase; NADPHox, NADPH
oxidase; PAI-1, plasminogen activator inhibitor-1; PG, proglucagon; TJ, tight junction; TLR, toll-like receptor; TNF, tumour necrosis factor.
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peptide content) in the proximal colon by a mechanism linked
to the differentiation of precursor cells into enteroendocrine
cells.33 44–48 In the present study, we additionally found that
changing gut microbiota using prebiotics is associated with an
increased endogenous production of the glucagon-like peptide-2
(GLP-2). GLP-2 is a 33 amino acid peptide, formed, as GLP-1,
from the cleavage of proglucagon peptide.57 GLP-2 is associated
with intestinal growth and adaptation in a variety of
pathological conditions, including post-resection intestinal
adaptation, coeliac disease, parental nutrition-induced intestinal
atrophy and inflammatory bowel disease.78–80 In addition, GLP-2
has also been demonstrated to enhance intestinal adaptation57
and to reduce the internalisation of enteric bacteria in INT-407
enterocytes in vitro model.81 Strikingly, the intestinotrophic
effects observed following prebiotic administration are similar
to the physiological effect of GLP-2. The increased GLP-2
Figure 8 Chronic GLP-2 treatment lowers endotoxaemia, improves gut permeability markers, and reduces systemic and hepatic inflammation,
oxidative stress and macrophage infiltration markers. (A) Plasma LPS concentrations (EU/ml); Cytokines and chemokines plasma levels (pg/ml):
(B) IL1a; (C) IL10; (D) MIP-1a; (E) MCP-1; (F,J) hepatic inflammation: TNFa, PAI-1 mRNA concentrations; (G,I) macrophage infiltration markers: TLR4,
CD68mRNA concentrations; (H,K) oxidative stress markers: iNOS, NADPHox mRNA; (L) immunohistochemistry score and (M) representative
immunofluorescence staining of the jejunum epithelial tight-junction proteins (ZO-1 and occludin) measured in ob/ob mice injected twice daily with a
saline vehicle (Ob-CT) or GLP-2 (Ob-GLP-2) for 12 days. Data are mean with the SEM. *Significantly different (p,0.05) from Ob-CT mice according to
the two-tailed Student t test. EU, endotoxin unit; GLP-2, glucogon-like protein-2; iNOS, inducible nitric oxide synthase; IL, interleukin;
LPS, lipopolysaccharide; MCP-1, monocyte chemoattractant protein-1; MIP-1a, macrophage inflammatory protein-1a; NADPHox, NADPH oxidase;
TLR, toll-like receptor; TNF, tumour necrosis factor.
Inflammatory bowel disease
1100 Gut 2009;58:1091–1103. doi:10.1136/gut.2008.165886
 on 10 August 2009 gut.bmj.comDownloaded from 
production is in accordance with our earlier study, where we
found that changing the gut microbiota of rats fed a high-fat
diet following a prebiotic treatment, doubled intestinal GLP-2
concentrations.46 Besides, here we found that the higher
endogenous GLP-2 production is associated with an improve-
ment of the mucosal barrier function, leading to improved tight
junctions and decreased plasma LPS concentrations and there-
fore blunted inflammatory and oxidative stresses. A recent
report demonstrates that a chronic treatment with GLP-2
protects rats against the ischaemia–reperfusion-induced endo-
toxaemia and inflammation, by an unknown mechanism.82
Our first experiment strongly suggests that the lower
metabolic endotoxaemia and the consequent low-grade inflam-
mation observed upon prebiotic feeding could be a mechanism
involving an enhanced endogenous GLP-2 production. Indeed,
we found that Ob-Pre fed mice exhibited a significant increase
of plasma GLP-2 levels and that this parameter negatively
correlates with markers of gut permeability. Along the same
line, we found a positive correlation between intestinal
proglucagon and tight-junction proteins mRNA (ZO-1, occlu-
din). Altogether, these data led us to postulate that the
prebiotic-induced intestinal proglucagon mRNA expression
and the consequent GLP-2 production may positively impact
on gut barrier integrity. Therefore, to investigate this hypoth-
esis, we performed a second set of experiments where we
treated mice concomitantly with the prebiotic and a GLP-2
antagonist. First, we confirm the improvement of inflammatory
markers following the prebiotic treatment; second, and more
importantly, we show that the GLP-2 antagonist completely
blocks the major features of the prebiotic treatment. Hence, in
absence of GLP-2 signalling, the prebiotic treatment failed to
reduce plasma LPS levels, and most of the hepatic inflammatory
and oxidative stress markers remained equivalent to the control
mice. In addition, the GLP-2 antagonist blocks the positive
effects of the prebiotic treatment on both intestinal tight-
junction proteins and proglucagon mRNA. Altogether, both set
of experiments strongly support that specific changes in gut
microbiota improve gut permeability and inflammatory tone by
a GLP-2 dependent mechanism.
To support the putative therapeutic effect of GLP-2 in the
context of a low-grade inflammation associated with obesity,
and in order to delineate the protective role of the GLP-2
independently of the modulation of the gut microbiota, we
chronically treated mice with GLP-2. This third set of
experiment clearly shows that GLP-2 treatment alone signifi-
cantly lowers inflammatory tone in obese mice. We found that
GLP-2 treated mice exhibited a lower metabolic endotoxaemia,
and a lower systemic and hepatic inflammatory tone. These
features were associated with a strong positive effect of GLP-2
on the tight-junction proteins distribution. This set of experi-
ments demonstrates that GLP-2 can be useful to treat the
altered gut barrier observed in obesity and diabetes, and
therefore could lower the inflammatory tone associated with
these diseases. It would be interesting to see whether the
magnitude of those effects is similar in other models such as
diet-induced obesity and diabetes (ie, non-leptin-deficient
models).
While the molecular and cellular mechanisms underlying the
effect of GLP-2 on the tight junctions and the gut barrier
function remained to define, several hypotheses can be
postulated. GLP-2 increases the rate of crypt cell proliferation,
villus elongation and reduces apoptosis, leading to improved
barrier function.83 It has been proposed that insulin-like growth
factor (IGF)-I acts as an essential target of GLP-2. Recent data
have shown that mice lacking IGF-I were resistant to GLP-2-
induced intestinal growth, crypt–villus height, and crypt cell
proliferation. Furthermore, GLP-2 administration increases
intestinal IGF-I secretion in vitro and enhances intestinal
IGF-I mRNA transcript levels both in vitro and in vivo.84 In
addition to this potential mechanism, data suggest that the
downstream molecular mechanism by which GLP-2 receptor
activation controls barrier function could be related to the
activation of the b-catenin signalling pathway.39 Nonetheless,
further studies are required to fully characterise the mechanisms
through which GLP-2 improves gut barrier function.
Together, using the complementary approaches of the specific
modulation of the gut microbiota, and of the pharmacological
inhibition or activation of the GLP-2 receptor, our findings
strongly suggest that GLP-2 participates to the modulation of
the gut barrier function and the consequent systemic and
hepatic inflammatory phenotype associated with obesity.
In addition, these data demonstrate that a selective modula-
tion of the gut microbiota improves intestinal permeability and
inflammatory markers during obesity and diabetes, via an
unexpected mechanism such as higher GLP-2 endogenous
production.
Thus, we propose that a selective gut microbiota modulation
controls and increases endogenous production of the intestino-
trophic proglucagon derived peptides GLP-2, and consequently
improves gut barrier functions by a GLP-2-dependent mechan-
ism. These new findings demonstrate the usefulness of
developing specific therapeutic strategies using GLP-2 to tackle
metabolic endotoxaemia and disorders associated with obesity
and diabetes, and that gut microbiota modulation could be an
interesting tool in this context.
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A gastrointestinal cause for heart
failure
CLINICAL PRESENTATION
A 67-year-old man presented with worsening shortness of
breath on exertion and peripheral oedema of 3 months
duration. He had evidence of heart failure including raised
jugular venous pressure, gallop rhythm and bilateral pedal
oedema. A non-tender liver was palpable about 2–3 cm below
the costal margin in the mid-clavicular line. Laboratory
investigations revealed iron deficiency anaemia (haemoglobin
6.1 g/dl, mean corpuscular volume 71 fl) and a minimally raised
alkaline phosphatase of 130 IU/l (normal range, 25–120 IU/l).
His serum ferritin was 10 ng/ml (normal range, 15–250 ng/ml).
Transthoracic echocardiogram demonstrated evidence of
hyperdynamic left ventricle and biventricular failure. Multiple
enhancing ‘‘lesions’’ within the liver with enhancement of the
hepatic veins and inferior vena cava was evident on the arterial
phase of computerised tomography of the abdomen (fig 1).
QUESTION
What is your diagnosis?
See page 1128 for the answer.
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Figure 1 Multiple enhancing ‘‘lesions’’ within the liver (A), followed by
enhancement of hepatic veins and inferior vena cava (B) on arterial
phase of computed tomography of liver.
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